GAITHERSBURG, Md., Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen's 44th Annual Health Care Conference.
Conference Details:
|
|
|
Fireside Chat
|
|
Date:
| Wednesday, March 6, 2024
|
Time:
| 1:30 – 2:00 p.m. Eastern Standard Time (EST)
|
Location:
| Boston Marriott Copley Place in Boston, Massachusetts
|
Moderator:
| Brendan Smith, Ph.D., Vice President, Biotechnology Equity Research
|
Novavax participant:
| John Jacobs, President and Chief Executive Officer
|
|
|
|
Conference
|
|
Event:
| Investor Meetings
|
Date:
| Wednesday, March 6, 2024
|
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes a vaccine for COVID-19 and influenza combined. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-td-cowens-44th-annual-health-care-conference-302076367.html
SOURCE Novavax, Inc.
